EAST AFRICAN JOURNAL OF NURSING

https://doi.org/10.58460/eajn.v1i01.134

Open Access

PERSPECTIVES ARTICLE

MJM BIOLABS

The Role of Vaccines in Pneumonia Prevention in Kenya: Progress, Challenges, and Future Directions

Michael Walekhwa[1], Meshack Shiundu[2], Valerie Suge[3]

Authors' Affiliation

[1]Department of Biomedical Sciences, School of Medicine and Health Sciences, Kabarak University

[2]Department of Medical Laboratory Sciences, Kenya Medical Training College

[3]Department of Nursing, School of Medicine and Health Sciences, Kabarak University

Article History

Submitted: 10th January 2025

Accepted: 28th January 2025

Published Online: 29th January 2025

To read this paper online, please scan the QR code below:

ABSTRACT

Pneumonia remains a leading cause of morbidity and mortality in Kenya, particularly among children under five years of age. Vaccination has been central to pneumonia prevention, with significant progress achieved through the introduction of key vaccines such as the pneumococcal conjugate vaccine (PCV), *Haemophilus influenzae* type b (Hib) vaccine, and measles vaccine. Despite these advancements, the burden of pneumonia persists, and challenges such as vaccine coverage disparities, logistical barriers, vaccine hesitancy, and emerging threats like antimicrobial resistance (AMR) continue to impede progress. This article provides a comprehensive perspective on the current status of pneumonia vaccination in Kenya, highlighting progress, challenges, and actionable recommendations. The introduction of PCV-10 in 2011 and its subsequent rollout has led to a marked reduction in invasive pneumococcal disease (IPD) and pneumonia hospitalizations. Similarly, the Hib vaccine, integrated into the pentavalent vaccine, has significantly reduced Hib-related pneumonia and meningitis cases. However, disparities in vaccine access, particularly in rural and underserved areas, remain a critical issue. Limited cold chain infrastructure, insufficient healthcare personnel, and vaccine hesitancy fueled by misinformation contribute to suboptimal coverage. To address these challenges, the we emphasize strengthening healthcare infrastructure, improving surveillance systems, and leveraging digital health technologies to enhance vaccine delivery and monitoring. Community engagement and education are highlighted as critical strategies to address vaccine hesitancy and build public trust. The article also underscores the importance of integrating vaccination efforts with broader health programs, such as maternal and child health initiatives, to improve outcomes. Future directions include transitioning to updated vaccine formulations, expanding access to pneumococcal polysaccharide vaccines (PPSVs) for high-risk populations, and fostering local research to address emerging threats.

Key Words: Pneumonia Vaccination; Pneumococcal Conjugate Vaccine; Vaccine Hesitancy; Healthcare Infrastructure

This open access article is published by MJ&M Biolabs, Kenya © 2025 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC- BY-NC-SA) license.

INTRODUCTION

Pneumonia remains one of the leading causes of morbidity and mortality globally, particularly among children under five years of age and in low- and middle-income countries (LMICs) (Marangu and Zar, 2019). In Kenya, the burden of pneumonia is substantial, accounting for a significant proportion of hospital admissions and deaths in children, despite advances in healthcare delivery and public health interventions (Marangu-Boore et al., 2024). The World Health Organization (WHO) estimates that pneumonia accounts for approximately 15% of all child deaths worldwide, with Sub-Saharan Africa bearing a disproportionate share of the disease burden (Zar and Ferkol, 2014). This public health challenge is exacerbated by factors such as poverty, malnutrition, inadequate access to healthcare, and the emergence of antimicrobial resistance (AMR).

Vaccination is a cornerstone of pneumonia prevention, with pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine playing pivotal roles in reducing the incidence of pneumonia caused by these pathogens (Deghmane and Taha, 2021). In Kenya, the introduction of these vaccines into the national immunization program has had a measurable impact on reducing pneumonia-related morbidity and mortality. However, achieving and maintaining optimal vaccination coverage remains a challenge due to socio-economic disparities, logistical barriers, and vaccine hesitancy within certain populations. Moreover, surveillance systems are often inadequate to monitor the full impact of these vaccines and identify gaps in their implementation.

We reviewed progress in pneumonia prevention through vaccination in Kenya, analyzed challenges affecting immunization effectiveness, and proposed strategies to improve coverage and integration into broader control efforts.

CURRENT STATUS OF PNEUMONIA VACCINES IN KENYA

Vaccination is a cornerstone of pneumonia prevention, with several vaccines currently in use to combat this disease. These include pneumococcal conjugate vaccines (PCVs), Haemophilus influenzae type b (Hib) vaccines, the measles vaccine, seasonal influenza vaccines, and pneumococcal polysaccharide vaccines (PPSVs) for specific populations (Gadama et al., 2021).

The pneumococcal conjugate vaccine (PCV), introduced in Kenya's routine immunization program in 2011, targets *Streptococcus pneumoniae*, a leading cause of severe pneumonia. PCV-10 is administered in three doses at 6, 10, and 14 weeks of age (Walekhwa et al., 2015). Since its introduction, PCV has significantly reduced invasive pneumococcal disease (IPD), pneumonia hospitalizations, and deaths. However, disparities in coverage remain, particularly in rural and underserved areas due to logistical challenges, vaccine hesitancy, and healthcare access limitations. Kenya has also begun transitioning to PCV-13 in some regions, which provides broader protection against additional pneumococcal serotypes.

The pneumococcal polysaccharide vaccine (PPSV23), designed to protect against 23 pneumococcal serotypes, is primarily recommended for high-risk groups, including older adults, individuals with chronic illnesses, and immunocompromised populations (Daniels et al., 2016). While not part of Kenya's routine immunization schedule for the general population, PPSV23 is increasingly used in clinical settings to prevent pneumonia among vulnerable groups, such as HIV-positive patients and individuals with sickle cell disease. Expanding its targeted use could significantly enhance pneumonia prevention among adults and at-risk populations.

The *Haemophilus influenzae* type b (Hib) vaccine, introduced in 2001 as part of the pentavalent vaccine, has been instrumental in reducing pneumonia and meningitis caused by *Haemophilus influenzae (Ndiritu et al., 2006)*. This vaccine, administered in three doses during infancy, has significantly reduced Hib-related disease burden in children. However, maintaining consistent supply chains and addressing coverage disparities remain ongoing challenges.

The measles vaccine also plays an indirect but vital role in pneumonia prevention (Mina, 2017). Measles infections often lead to severe respiratory complications, including pneumonia. Administered in two doses (at 9 and 18 months), this vaccine has significantly reduced the incidence of pneumonia associated with measles outbreaks in Kenya. The seasonal influenza vaccine, although not part of Kenya's routine immunization program, is available for high-risk groups, including healthcare workers, pregnant women, the elderly, and individuals with chronic diseases. Widening access to this vaccine could further mitigate the risk of viral pneumonia, particularly during influenza outbreaks.

CHALLENGES IN PNEUMONIA VACCINE IMPLEMENTATION

Despite significant progress in pneumonia prevention through vaccination, several challenges hinder the effective implementation and impact of pneumonia vaccines in Kenya. These challenges span across logistical, socio-economic, infrastructural, and systemic dimensions, affecting the ability to achieve optimal coverage and reduce disease burden.

One of the most significant challenges is the inadequacy of healthcare infrastructure, particularly in rural and hard-to-reach areas (Okech, 2017). Vaccination programs require a reliable cold chain system to maintain the potency of vaccines such as the pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine. In many parts of Kenya, especially in arid and semi-arid regions, frequent power outages, lack of refrigeration facilities, and insufficient transportation systems disrupt vaccine storage and delivery. Inadequate healthcare personnel further compounds these logistical challenges. Many rural health facilities are understaffed, with healthcare workers often overburdened by competing priorities, limiting their ability to conduct vaccination outreach and follow-up activities.

Socio-economic factors significantly impact vaccine accessibility. Communities in marginalized areas often face barriers such as high transportation costs to reach health facilities, loss of income due to time spent accessing healthcare, and limited awareness of the benefits of vaccination (Gachathi et al., 2024). These barriers disproportionately affect vulnerable populations, including children in pastoralist communities, urban slums, and conflict-prone areas.

Vaccine hesitancy is an emerging challenge, driven by misinformation, cultural beliefs, and distrust in healthcare systems (Nuwarda et al., 2022). Myths surrounding vaccine safety, fears of adverse effects, and religious or cultural misconceptions have led to resistance in some communities. The proliferation of misinformation through social media and other channels has further exacerbated vaccine hesitancy, undermining public health efforts to promote immunization. Sustaining vaccine programs requires significant financial resources, which are often limited in low- and middle-income countries like Kenya. While initiatives such as Gavi, the Vaccine Alliance, have supported vaccine procurement and implementation, gaps remain in funding for operational costs, outreach programs, and surveillance systems. Additionally, Kenya faces challenges in transitioning to self-financing

these programs as external donor support diminishes over time.

Robust disease surveillance and vaccine coverage data are critical for evaluating the impact of vaccination programs and identifying areas of improvement (Scobie et al., 2020). However, Kenya's surveillance systems often lack the capacity to provide comprehensive, real-time data on pneumonia incidence, vaccination coverage, and vaccine-preventable disease outcomes. For example, the lack of detailed serotype surveillance limits the ability to monitor the impact of pneumococcal conjugate vaccines and detect potential shifts to non-vaccine serotypes. The rise of antimicrobial resistance (AMR) poses a unique challenge to pneumonia prevention efforts. AMR increases the severity and treatment complexity of bacterial pneumonia, emphasizing the need for effective vaccination to prevent infections. However, the emergence of non-vaccine serotypes and resistant strains of Streptococcus pneumoniae may reduce the long-term efficacy of current vaccines, necessitating continuous research and development of updated formulations.

Vaccination programs in Kenya often operate in silos, with limited integration into broader health initiatives (Awuonda, 2015). For instance, maternal and child health programs, nutrition interventions, and community-based healthcare services offer opportunities to enhance vaccine uptake but are not consistently leveraged to their full potential. Lack of cross-sectoral collaboration reduces the efficiency and reach of immunization programs. Geographic disparities in vaccine coverage are evident, with urban centers generally achieving higher coverage rates than rural and remote areas. Marginalized groups, such as nomadic communities, often face logistical challenges that limit vaccine access. These inequities undermine efforts to achieve universal immunization and leave vulnerable populations at greater risk of pneumonia.

PROGRESS AND SUCCESS STORIES

Studies have shown a substantial decline in invasive pneumococcal disease (IPD) and pneumonia hospitalizations among children under five years of age since the vaccine's rollout. Similarly, the inclusion of the Haemophilus influenzae type b (Hib) vaccine as part of the pentavalent vaccine in 2001 has drastically reduced cases of Hib-related pneumonia and meningitis. These vaccines have contributed significantly to achieving immunization coverage rates that are among the highest in Sub-Saharan Africa, with urban areas leading in vaccine uptake.

Community-driven initiatives have also been instrumental in increasing vaccine awareness and uptake. Programs such as door-to-door vaccination campaigns and maternal health education have effectively reached populations in underserved regions. For example, targeted outreach in arid and semi-arid areas has improved vaccine coverage among nomadic communities, who were previously at high risk of vaccine-preventable diseases. Partnerships between the Kenyan government, international organizations, and local stakeholders have strengthened vaccine delivery systems. Investments in cold chain infrastructure and training for healthcare workers have improved the reliability and efficiency of immunization services. Moreover, Kenya's early adoption of digital health tools for tracking immunization coverage and stock management has enhanced the monitoring and distribution of vaccines.

FUTURE DIRECTIONS AND RECOMMENDATIONS

As Kenya continues to tackle pneumonia through vaccination, a multifaceted approach is essential to sustain progress, address remaining challenges, and enhance the impact of immunization programs. The following recommendations outline future directions to

strengthen pneumonia prevention and control:

Efforts must focus on addressing geographic and socio-economic disparities in vaccine coverage. Targeted strategies, such as mobile clinics and outreach programs in rural, remote, and nomadic communities, are critical to reaching underserved populations. Improving healthcare infrastructure, including cold chain systems and reliable transportation, will ensure vaccine availability in all regions.

Community education and engagement campaigns are essential to combat vaccine hesitancy fueled by misinformation. Tailored communication strategies that involve community leaders, religious groups, and healthcare workers can help build trust and promote the benefits of vaccines. Leveraging mass media and social media platforms to disseminate accurate information can further enhance public confidence.

Robust disease surveillance systems are crucial for tracking vaccine-preventable pneumonia cases and identifying gaps in immunization coverage. Expanding serotype-specific surveillance for *Streptococcus pneumoniae* and Haemophilus influenzae will help monitor the effectiveness of pneumococcal conjugate vaccines and identify emerging non-vaccine serotypes. Strengthening data collection and reporting through digital tools and integrating these systems into national health databases will improve program management and decision-making.

Emerging threats, such as antimicrobial resistance (AMR) and shifts in pneumococcal serotypes, necessitate ongoing evaluation of current vaccine formulations. Kenya should prioritize transitioning to updated vaccines, such as PCV-13 or PCV-20, which offer broader serotype protection. Research into locally relevant pathogens and AMR trends will guide vaccine development and deployment strategies.

Integrating immunization efforts with maternal and child health programs, nutrition interventions, and disease prevention initiatives can enhance their impact. For example, combining vaccination campaigns with nutritional supplementation and health screenings can address multiple determinants of pneumonia simultaneously, improving overall health outcomes.

Kenya should invest in local research capacity to generate context-specific evidence on pneumonia prevention. Collaborations with academic institutions and global partners can support studies on vaccine efficacy, cost-effectiveness, and the development of new vaccines targeting local strains. Strengthening partnerships with international stakeholders will also facilitate access to emerging vaccines and technologies.

Long-term success in pneumonia prevention requires consistent financial support. The Kenyan government should prioritize increased budget allocations for immunization programs and explore innovative financing mechanisms, such as public-private partnerships, to supplement existing resources. Transitioning to self-sustaining vaccine procurement as donor support declines is critical to maintaining progress.

Digital health technologies, such as electronic immunization registries and real-time stock management systems, can optimize vaccine delivery and minimize wastage. Mobile health (mHealth) applications can be used to remind caregivers about vaccination schedules and track immunization coverage at the community level.

REFERENCES

Awuonda, O. B. (2015). *Challenges of implementing the social pillar strategy of the Kenya Vision 2030 in the devolved health sector in Kisumu County.* University of Nairobi,

Daniels, C. C., Rogers, P. D., & Shelton, C. M. (2016). A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. *The Journal of Pediatric Pharmacology and Therapeutics, 21*(1), 27-35.

Deghmane, A.-E., & Taha, M.-K. (2021). Invasive bacterial infections in subjects with genetic and acquired susceptibility and impacts on recommendations for vaccination: a narrative review. *Microorganisms, 9*(3), 467.

Gachathi, S. N., Walekhwa, M., & Mugambi, J. (2024). Performance of Community Health Volunteers in the Delivery of Healthcare Services During the Covid-19 Pandemic in Nakuru, Kenya: A Cross-Sectional Analysis. *Journal of Clinical Care and Medical Advancement, 2*(1), 1-12.

Gadama, D., Mvalo, T., & Ginsburg, A. S. (2021). Haemophilus influenzae type b and pneumococcal conjugate vaccination coverage in children aged 2-59 months in Malawi. *Human Vaccines & Immunotherapeutics, 17*(2), 397-399.

Marangu-Boore, D., Mwaniki, P., Isaaka, L., Njoroge, T., Mumelo, L., Kimego, D., . . . Wanyama, C. (2024). Characteristics of children readmitted with severe pneumonia in Kenyan hospitals. *BMC Public Health, 24*(1), 1324.

Marangu, D., & Zar, H. J. (2019). Childhood pneumonia in low-and-middle-income countries: An update. *Paediatric respiratory reviews, 32*, 3-9.

Mina, M. J. (2017). Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits. *Journal of Infection, 74*, S10-S17.

Ndiritu, M., Cowgill, K. D., Ismail, A., Chiphatsi, S., Kamau, T., Fegan, G., . . . Scott, J. A. G. (2006). Immunization coverage and risk factors for failure to immunize within the Expanded Programme on Immunization in Kenya after introduction of new Haemophilus influenzae type b and hepatitis b virus antigens. *BMC Public Health, 6*, 1-8.

Nuwarda, R. F., Ramzan, I., Weekes, L., & Kayser, V. (2022). Vaccine hesitancy: contemporary issues and historical background. *Vaccines, 10*(10), 1595.

Okech, T. C. (2017). Devolution of public health care services in Kenya and its implication on universal health coverage. *IOSR Journal of Pharmacy, 7*(5/1), 9-23.

Scobie, H. M., Edelstein, M., Nicol, E., Morice, A., Rahimi, N., MacDonald, N. E., . . . Jawad, J. (2020). Improving the quality and use of immunization and surveillance data: Summary report of the Working Group of the Strategic Advisory Group of Experts on Immunization. *Vaccine, 38*(46), 7183-7197.

Walekhwa, M., Muturi, M., & Bukusi, E. (2015). Immunogenicity of 10-valent pneumococcal conjugate vaccine among infants attending Mbagathi District Hospital, Kenya. *F1000Research, 4*, 165.

Zar, H. J., & Ferkol, T. W. (2014). The global burden of respiratory disease—impact on child health. In (Vol. 49, pp. 430-434): Wiley Online Library.